La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Ipca Laboratories Gestion

Gestion contrôle des critères 2/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Pranay Godha

Directeur général

₹65.2m

Rémunération totale

Pourcentage du salaire du PDG	25.7%
Durée du mandat du directeur général	1.3yrs
Propriété du PDG	0.7%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	9.9yrs

Mises à jour récentes de la gestion

Recent updates

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Jun 07

These 4 Measures Indicate That Ipca Laboratories (NSE:IPCALAB) Is Using Debt Reasonably Well

Sep 20

Is Now The Time To Put Ipca Laboratories (NSE:IPCALAB) On Your Watchlist?

Aug 09

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Jun 08

How Does Ipca Laboratories Limited (NSE:IPCALAB) Stand Up To These Simple Dividend Safety Checks?

Mar 26

Do Ipca Laboratories's (NSE:IPCALAB) Earnings Warrant Your Attention?

Mar 13

Trade Alert: The Compliance Officer Of Ipca Laboratories Limited (NSE:IPCALAB), Harish Kamath, Has Sold Some Shares Recently

Feb 28

Ipca Laboratories Limited's (NSE:IPCALAB) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?

Feb 23

Does Ipca Laboratories' (NSE:IPCALAB) CEO Salary Compare Well With Industry Peers?

Feb 11

Could The Ipca Laboratories Limited (NSE:IPCALAB) Ownership Structure Tell Us Something Useful?

Jan 30

The Ipca Laboratories (NSE:IPCALAB) Share Price Is Up 264% And Shareholders Are Boasting About It

Jan 15

Ipca Laboratories (NSE:IPCALAB) Seems To Use Debt Rather Sparingly

Dec 31

Don't Ignore The Fact That This Insider Just Sold Some Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Dec 16

The Case For Ipca Laboratories Limited (NSE:IPCALAB): Could It Be A Nice Addition To Your Dividend Portfolio?

Dec 13

This Insider Has Just Sold Shares In Ipca Laboratories Limited (NSE:IPCALAB)

Nov 28

Analyse de la rémunération des PDG

Comment la rémunération de Pranay Godha a-t-elle évolué par rapport aux bénéfices de Ipca Laboratories?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Jun 30 2024	n/a	n/a	₹6b
Mar 31 2024	₹65m	₹17m	₹5b
Dec 31 2023	n/a	n/a	₹6b
Sep 30 2023	n/a	n/a	₹5b
Jun 30 2023	n/a	n/a	₹5b
Mar 31 2023	₹51m	₹13m	₹5b
Dec 31 2022	n/a	n/a	₹5b
Sep 30 2022	n/a	n/a	₹6b
Jun 30 2022	n/a	n/a	₹7b
Mar 31 2022	₹46m	₹12m	₹9b
Dec 31 2021	n/a	n/a	₹9b
Sep 30 2021	n/a	n/a	₹10b
Jun 30 2021	n/a	n/a	₹10b
Mar 31 2021	₹32m	₹8m	₹11b
Dec 31 2020	n/a	n/a	₹11b
Sep 30 2020	n/a	n/a	₹10b
Jun 30 2020	n/a	n/a	₹9b
Mar 31 2020	₹33m	₹8m	₹6b
Dec 31 2019	n/a	n/a	₹6b
Sep 30 2019	n/a	n/a	₹6b
Jun 30 2019	n/a	n/a	₹5b
Mar 31 2019	₹29m	₹8m	₹4b
Mar 31 2018	₹25m	₹7m	₹2b

Rémunération vs marché: La rémunération totale de Pranay ($USD 777.39K ) est dans la moyenne des entreprises de taille similaire sur le marché Indian ($USD 598.04K ).

Rémunération et revenus: La rémunération de Pranay a augmenté de plus de 20 % au cours de l'année écoulée.

PDG

Pranay Godha (52 yo)

1.3yrs

Titularisation

₹65,228,222

Compensation

Mr. Pranay Premchand Godha served as the President of APIs & Generics at Ipca Laboratories Limited and joined it on April 16, 2003. He serves as Non-Executive, Non-Independent Director at Unichem Laborator...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Premchand Godha	Executive Chairman	48.8yrs	₹123.00m	2.29% ₹ 8.2b
Pranay Godha	CEO, MD & Executive Director	15.8yrs	₹65.23m	0.67% ₹ 2.4b
Ajit Kumar Jain	CFO, MD & Executive Director	30yrs	₹84.44m	0.017% ₹ 59.0m
Prashant Godha	Executive Director	13yrs	₹69.76m	0.62% ₹ 2.2b
Manisha Premnath	Independent & Non-Executive Director	9.9yrs	₹900.00k	pas de données
Narendra Mairpady	Additional Independent Director	1.8yrs	₹1.25m	pas de données
Kamal Seth	Lead Independent Director	5.4yrs	₹1.60m	0.00067% ₹ 2.4m
Swati Patankar	Independent Director	less than a year	₹250.00k	pas de données
Vivek Shiralkar	Independent Director	less than a year	pas de données	pas de données

9.9yrs

Durée moyenne de l'emploi

67.5yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de IPCALAB sont considérés comme expérimentés (ancienneté moyenne 9.9 ans).

Ipca Laboratories Gestion

Gestion contrôle des critères 2/4

Informations clés

Mises à jour récentes de la gestion

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

CFO, MD & Executive Director recently sold ₹22m worth of stock

Recent updates

Price target increased by 8.6% to ₹1,320

Ipca Laboratories Limited Approves Appointment of Vivek Shiralkar as an Independent Director

Upcoming dividend of ₹2.00 per share

Ipca Laboratories Limited to Report Q1, 2025 Results on Aug 13, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Ipca Laboratories Limited, Annual General Meeting, Aug 13, 2024

Less than half of directors are independent

Ipca Laboratories' (NSE:IPCALAB) Solid Earnings Have Been Accounted For Conservatively

Ipca Laboratories Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Full year 2024 earnings released: EPS: ₹25.82 (vs ₹18.58 in FY 2023)

Ipca Laboratories Limited (NSE:IPCALAB) Not Lagging Market On Growth Or Pricing

Ipca Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director

Price target increased by 9.1% to ₹1,097

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Investors Interested In Ipca Laboratories Limited's (NSE:IPCALAB) Earnings

Ipca Laboratories Limited to Report Q3, 2024 Results on Feb 14, 2024

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

CFO, MD & Executive Director recently sold ₹22m worth of stock

Price target increased by 9.7% to ₹987

Upcoming dividend of ₹2.00 per share at 0.2% yield

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Ipca Laboratories Limited to Report Q2, 2024 Results on Nov 10, 2023

Ipca Laboratories Limited Appoints Hitesh Kumar Maheshwari as President R&D (Formulations)

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Ipca Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q4, 2023 Results on May 29, 2023

Price target decreased by 7.1% to ₹858

Investor sentiment deteriorates as stock falls 15%

Ipca Laboratories (NSE:IPCALAB) Has A Pretty Healthy Balance Sheet

Consensus EPS estimates fall by 21%

Third quarter 2023 earnings: EPS misses analyst expectations

Ipca Laboratories Limited to Report Q3, 2023 Results on Feb 14, 2023

Ipca Laboratories Limited (BSE:524494)acquired additional 6.53% stake in Trophic Wellness Pvt. Ltd. for INR 105.8 million.

Insufficient new directors

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited Declares Interim Dividend for the Financial Year 2022-23, Payable on December 7, 2022

Ipca Laboratories Limited to Report Q2, 2023 Results on Nov 11, 2022

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director

Insider recently sold ₹1.7m worth of stock

Here's Why Ipca Laboratories (NSE:IPCALAB) Can Manage Its Debt Responsibly

Estimating The Intrinsic Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Ipca Laboratories Limited Approves Interim Dividend as Final Dividend for Financial Year Ended 31St March, 2022

Now 20% undervalued

Ipca Laboratories Limited Announced Demise of Dev Parkash Yadava, Non-Executive and Independent Director

Ipca Laboratories Limited to Report Q1, 2023 Results on Aug 10, 2022

Now 20% undervalued after recent price drop

Full year 2022 earnings: EPS misses analyst expectations

Ipca Laboratories Limited, Annual General Meeting, Aug 10, 2022

Now 20% undervalued after recent price drop

Is Ipca Laboratories (NSE:IPCALAB) A Risky Investment?

Now 20% undervalued after recent price drop

Price target decreased to ₹1,067

Calculating The Fair Value Of Ipca Laboratories Limited (NSE:IPCALAB)

Full year 2022 earnings: EPS misses analyst expectations

Insufficient new directors

CFO, Joint MD & Executive Director recently sold ₹21m worth of stock

Does Ipca Laboratories (NSE:IPCALAB) Have A Healthy Balance Sheet?

Price target decreased to ₹1,177

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Ipca Laboratories Limited to Report Q3, 2022 Results on Feb 14, 2022

Ipca Laboratories Limited (BSE:524494) made an offer to acquire additional 26% stake in Lyka Labs Limited (BSE:500259) from Mayank J Shah, Shruti M Shah, Prasham M Shah and others for approximately INR 970 million.

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS ₹19.73 (vs ₹21.08 in 2Q 2021)